Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Psych MCQs > Pharmacology > Flashcards

Pharmacology Flashcards

1
Q

Levidopa/Carbidopa

A

Used in Parkison’s.
Levodopa = metabolic precursor of dopamine.
Carbidopa = peripheral decarboxylase inhibitor, which prevents peripheral breakdown to increase CNS levels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Selegline

A

MAO-B inhibitor
Used in early Parkinson’s as breaks down dopamine selectively.
Caution with SSRIs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Entacapone

A

Used in Parkinson’s to increase the half-life of L-dopa so there are less motor fluctuations and dyskinesia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Donepezil

A

Selective reversible AChE inhibitor.
Binds at peripheral site.
Given once daily.
Dose 5-10mg.
ADRs: N+V, insomnia, diarrhoea, bradycardia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Rivastigmine

A

Reversible AChE inhibitor. Also acts on butylcholinesterase.
Given BD.
Dose 1.5-6mg BD.
Also available as transdermal patch.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Galantamine

A

Selective competitive AChE inhibitor. Also acts as antagonist at nicotinic receptors.
Given BD.
Dose 12mg BD.
ADRs: N+V.
Not subsidised in NZ.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Memantine

A

NMDA-receptor antagonist.
Blocks excitotoxic glutamate activity.
Indicated in moderate/severe dementia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Acetylcholinesterase inhibitors

A

Indications: Alzheimer’s, Lewy body, Parkinson’s, vascular dementia.
Better evidence in mild/mod than severe.
Contraindications: FTD, pure alcoholic dementia, large strokes, MCI.
Stabilise symptoms for 6-12 months, with subtle improvement in 50% (sx improved include apathy, spontaneity, delusions/hallucinations).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bupropion

A

Dopamine + NA reuptake inhibitor.
Indicated in smoking cessation (reduces withdrawals, post-cessation weight gain) and depression.
ADRs: psychiatric sx, seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Varenicline

A

Nicotine α4β2 partial receptor agonist
Indicated in smoking cessation
ADRs: nausea, dry mouth, depression/SI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Disulfiram

A

Prevents ETOH breakdown by aldehyde dehydrogenase.
Indicated in alcohol abuse as negative reinforcement.
ADRs: can affect liver and thyroid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Naltrexone

A

Opiate receptor antagonist
Used in alcohol dependence as reduces pleasure, no withdrawal, no negative effects, minimal ADRs/interactions
But high relapse rate, withdrawal sx if using opiates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Acamprosate

A

GABA analogue, acts on GABA and glutamate systems, allosteric modulator of GABA-A
Used in alcohol dependence
Dose: <60kg = 333mg TDS, >60kg = 666mg TDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Lofexidine

A

α2A adrenergic receptor agonist
Can be used in opiate withdrawal to reduce sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Methadone

A

Full opioid agonist
Start low and give incremental doses as per withdrawal scale
Usual dose 60-120mg, can take 6 weeks to stabilise
Need to monitor LFTs and QTc
Advantages: well absorbed, long half-life (OD dosing, in urine for 3 days), used in pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Suboxone

A

Buprenorphine (long acting partial mu agonist, weak kappa agonist, delta agonist) + naloxone (opioid antagonist).
Diminishes cravings and helps with withdrawal.
Safe in overdose due to ceiling effect. Blocks other opioid agonists in dose-dependent fashion. Can precipitate withdrawal so first dose given when already in withdrawal.
Usual dose 2-8mg. Half-life 24-37 hours.
Advantages: milder withdrawal, alleviates cravings, long-acting, greater blockade effect
Caution with CYP3A4 inhibitors (inducer).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

First generation antipsychotics

A

Predominantly dopamine blockers in mesolimbic pathway (to reduce psychotic sx), but not selective, so also act on mesocortical (secondary negative sx, depression, cognitive dysfunction), nigrostriatal (EPSE) and tuberoinfundibular (raised PL) pathways.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Second generation antipsychotics

A

Combination of D2 blockade plus 5HT-2 blockade, which causes reciprocal increase in dopamine, so effects more specific to mesolimbic pathway, with reduced side effects.
Variable in how tightly they bind D2 and how quickly they dissociate.
If used in high doses, dopamine blockade exceeds 60-80%, and they start to act as typical antipsychotics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Benztropine

A

Anticholinergic and antihistamine
Used in movement disorders, such as parkinsonism and dystonia, and EPSE, such as akathisia.
Not useful in tardive dyskinesia.
ADRs: dry mouth, blurry vision, nausea, constipation
Benztropine overdose presents with confusion, trouble swallowing, hot and dry skin, dilated pupils, tachycardia, urinary retention, irregular pulse, fainting or seizures.
Antidote = physostigmine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Tetrabenazine

A

Inhibits vesicular monoamine transporter and depletes presynaptic dopamine.
Used for treatment of hyperkinetic movement disorders, such as tardive dyskinesia, hemiballismus, Huntington’s chorea, tics.
Depletes dopamine so can lead to depression/SI.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Bromocriptine

A

Partial D2 agonist
Used in NMS, as well as hyperprolactinaemia and acromegaly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Aripiprazole

A

Partial D2 agonist, 5HT-2A antagonist, partial 5HT-1A agonist.
High affinity for receptor but low intrinsic activity (Goldilock’s effect).
Can be used as augmentation to reduce side effects.
Highly protein bound (99%).
Long half-life (94 hours).
CYP3A4 substrate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Amisulpride

A

Selective D2/D3 antagonist.
D3 are presynaptic autoreceptors in frontal lobe so antagonism increases dopamine.
At <400mg, amisulpride enhances dopamine transmission.
At higher doses, it blocks D2 and can cause raised PL.
Purely excreted renally. Can be used in hepatic disease. Avoid in renal impairment.
Given BD at doses >300mg to increase therapeutic effect and reduce adverse effects.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Chlorpromazine

A

D1/D2/D3/D4 antagonist
Also acts as antagonist of 5-HT, H1, alpha1-2, M1-M2
Highest risk of sunburn due to increased skin photosensivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Clozapine - Mechanism + Metabolism

A

D2 and 5HT-2 antagonist with hit-and-run mechanism (highest dissociation rate)
Highest affinity for D4
Potent anticholinergic
CYP1A2 - so caffeine increases levels and smoking reduces levels
CYP3A4 responsible for 35% of clozapine metabolism - so drug interactions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Clozapine - Side effects

A
  • Most epileptogenic antipsychotic
  • Agranulocytosis (usually first 18 weeks, contraindicated with carbamazepine)
  • Myocarditis (usually first 8 weeks)
  • Cardiomyopathy
  • VTE and PE
  • Constipation
  • Tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Flupenthixol

A

D2 antagonist, also acts on 5HT
Typical antipsychotic
Antidepressant effect at lower doses
Available as depot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Haloperidol

A

D2 antagonist
Typical antipsychotic
Can be used in renal and hepatic impairment, and in pregnancy (1st line for mania)
Indicated for tics in Tourette;s
Available as depot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Olanzapine

A

D2 and 5HT-2 antagonist, H1 blockade (sedating)
Can be used in renal impairment.
CYP1A2 involved (nicotine, caffeine).
Half-life 30 hours.
Highest passage across placenta of SGAs, associated with high birth weight, macrosomia, increased ICU admissions.
Need to monitor for post-injection syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Paliperidone

A

D2 and 5HT-2 antagonist
Major active metabolite of risperidone
Low potential for drug interactions as limited hepatic metabolism
Half-life 24-28 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Quetiapine

A

D2 (higher dissociation so lower risk of EPSE) and 5HT-2 antagonist, H1 blockade (sedating)
CYP3A4 involved
Half-life 6-12 hours so multiple daily dosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Risperidone

A

D2 and 5HT-2 antagonist
At higher doses, binds selectively to D2 so more risk of EPSE and high PL.
Potent alpha-1 blocker so first dose hypotensive effect.
Extensive first pass metabolism by CYP2D6 to 9-OH risperidone.
Half-life of metabolite = 24 hours.
Second highest passage across placenta.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Sertindole

A

Strong D2 and 5HT-2 antagonist
Potent alpha-1 blocker
Highest potential for QTc prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Sulpride

A

Dose-related antagonist at presynaptic D3 (<800mg/day) and postsynaptic D2 (>800mg/day).
Purely renally excreted. Avoid in renal impairment. Recommended in hepatic disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Trifluoperazine

A

D1/D2 antagonist
Typical antipsychotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Thioridazine

A

Not available due to highest risk of prolonged QTc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Ziprasidone

A

D2 and 5HT-2 antagonist, 5HT-1A agonist, monoamine reuptake inhibitor
Acts as antidepressant at low doses (due to MAOI effect).
Reduces weight through 5HT agonism.
High risk for prolonged QTc.
CYP3A4 involved.
Half-life = 7-12 hours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Zuclopenthixol

A

D1/D2 antagonist, 5HT-2 antagonist, alpha-1 adrenergic
Typical antipsychotic
Available as decanoate (depot), acetate (accuphase, effect peaks at 48-72 hours) and oral.
Interacts with paroxetine due to shared hepatic metabolism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Lurasidone

A

D2/D3 antagonist, 5HT-2A/5HT-7 antagonist, 5HT-1A partial agonist, alpha-2c antagonist
Atypical antipsychotic
Used in bipolar depression, alone or as an adjunct.
Low risk of weight gain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

SSRIs - Mechanism

A

Block SERT (serotonin reuptake transporter) so serotonin remains in synaptic cleft and can bind to various serotonin receptors.
Initially, there is an increase in signaling across synapses that use 5HT as main neurotransmitter.
With time, increased occupancy of post-synaptic 5HT receptor downregulates release of 5HT from presynaptic neurons, which ultimately leads to downregulation of postsynaptic 5HT receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Serotonin receptors involved in SSRIs

A

5HT1A = presynaptic autoreceptor, acts as brake.
5HT-2A = postsynaptic receptor, effects include anxiety, akathisia, emotional blunting, insomnia.
5HT-2C = postsynaptic, can lead to sexual dysfunction and anorexia.
5HT-3 = postsynaptic, can lead to nausea and diarrhoea, ligand gated.
5HT-7 = circadian rhythms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

SSRIs - side effects

A

Initial anxiety
Sleep disturbance
GI upset
Headaches
Hyponatraemia
GI bleeding
Sexual dysfunction

Side effects dominate when SSRI first started, but they should reduce as receptors down regulate.

Paroxetine has most weight gain and sexual side effects.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

SSRIs - Interactions

A

Enzyme inhibitors so can increase levels of clozapine, olanzapine, benzos, TCAs, methadone.
Do not prescribe with MAOIs due to risk of serotonin syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Mirtazapine - Mechanism

A

NASSA (NA serotonin specific antagonist)
At doses of 15-30mg, it is primarily a serotonin antagonist, so effects are:
- 5HT-2A = antianxiety, treats akathisia, improves slow wave sleep
- 5HT-2C = increased appetite, no sexual effects
- anti-H1 = increased appetite, sedation
At doses of 45-60mg, it primarily has a noradrenergic dopaminergic effect, by antagonising alpha-2 presynaptic receptor, increasing NA and dopamine => broad spectrum antidepressant.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Mirtazapine - Side effects

A

Sedation at low doses (H1).
Weight gain, increased appetite.
Agranulocytosis.
Caution in epilepsy.
No sexual dysfunction.
Minimal risk of serotonin syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

SNRIs - Mechanism

A

SNRIs = venlafaxine, duloxetine.
Serotonin noradrenergic reuptake inhibitors.
- Block SERT to increase serotonin.
- Block NET to increase NA and dopamine.
Broad spectrum effect.
Half-life 4-5 hours.

Venlafaxine predominantly acts as SSRI up to 225mg, then has SNRI effects above that.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

SNRIs - Side effects

A

Side effects of both SSRIs and dopamine-related effects (activation, agitation).
Sexual dysfunction.
Hypertension at doses >225mg.
Greater risk of discontinuation syndrome.
Caution in epilepsy (seizure risk).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Agomelatine - Mechanism

A

Melatonin agonist (M1/M2) = improves slow wave sleep.
5HT-2C antagonist
Also increases frontal lobe dopamine and NA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Agomelatine - Side effects

A

LFT derangement
No risk of serotonin syndrome
No sexual dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Tricyclics - Mechanism

A

Broad spectrum antidepressants
Act primarily as SNRIs by blocking SERT and NET.
Weak affinity for DAT.
Many also have high affinity as 5HT antagonists, alpha-1 adrenergic and NMDA receptors, and as sigma agonists.
Also have potent anticholinergic and antihistaminergic effects.

51
Q

Tricyclics - Examples

A

Amitriptyline, nortriptyline
Clomipramine, desipramine, imipramine
Dosulepine, doxepine

52
Q

MAOIs - Examples

A

Non-selective = phenelzine, tranylcypromine
Selective MAO-A = moclobemide
Selective MAO-B = selegline

53
Q

MAOIs - Mechanism

A

Broad spectrum antidepressants
- Inhibit MAO to prevent breakdown of monoamine neurotransmitters
- MAO-A preferentially acts on serotonin, melatonin, adrenaline and NA
- MAO-B preferentially acts on phenethylamine and other trace amines
- Dopamine equally affected by both

54
Q

MAOIs - Side effects

A

Hypertensive crisis - which can be fatal. Need to avoid eating food contained tyramine (cheese, fermented food, liver).

55
Q

NARIs

A

Atomoxetine (used in ADHD) and reboxetine.
Noradrenergic reuptake inhibitors
Can cause liver failure and SI

56
Q

Vortioxetine

A

SSRI + serotonin modulator, so blocks SERT to increase serotonin, but with minimal sexual dysfunction or weight gain.
5HT-7 antagonist = pro-cognitive effects.

57
Q

SARIs

A

Nefazodone and trazodone.
Serotonin antagonist and reuptake inhibitor (of 5HT, NA and dopamine).
Also antagonist alpha-1 adrenergic receptors.

58
Q

Buspirone

A

5HT-1A partial agonist with high affinity
Acts as a full agonist at presynaptic receptor, to decrease serotonin levels for anti-anxiety effect.
Acts as a partial agonist at postsynaptic receptors, for anti-depressant effects.
Also a D2 antagonist.

Half-life 2-12hours.
Can be used in depression, GAD.
Main side effect is dizziness (titrate dose slowly).

59
Q

Cyproheptadine

A

Antihistamine with anti-serotonergic effects (5HT-1 and 2 blockade).
Used in treatment of serotonin syndrome

60
Q

Lithium - Mechanism

A

Acts via “second messenger system”.
Effects include decreased NA release, increased 5HT synthesis, inhibition of excitatory neurotransmitters (dopamine, glutamate) and promotion of glutamate (inhibitory).
Likely has neuroprotective/neuroproliferative effects.

61
Q

Lithium - Pharmacology

A

Half-life 18-36 hours.
Peak plasma concentration at 1-2 hours (standard release) or 4-5 hours (ER).
Starting dose 250mg BD or 400mg nocte. Loading dose 20-30mg/kg.
Bioavailability 80-100%
Follows zero order kinetics
Almost exclusively excreted by kidney as free ion

62
Q

Lithium - Indications

A

Prophylaxis and treatment of mania, hypomania and depression in BPAD
Prophylaxis and treatment of unipolar depression
Augmentation agent to antidepressants

Note full prophylactic effect may take 6-12months

63
Q

Lithium - Plasma levels

A

Narrow therapeutic/toxic ratio
Levels taken on day 7, 12 hours post-dose.
Targets:
- 0.4-0.6 for tx of depression
- 0.6-08 for prophylaxis
- 0.8-1.2 for tx of mania

64
Q

Lithium - Toxicity

A

Level >1.5
Tremor, ataxia, dysarthria, nystagmus, renal impairment, convulsions, death.

65
Q

Lithium - Side effects

A

Common - polyuria, thirst, tremor, impaired memory/cognition, hair loss, acne
Serious - hypothyroidism, hyperparathyroidism, renal damage

66
Q

Lithium - Interactions

A

Avoid diuretics, ACEIs, ARBs, NSAIDs
All increase lithium level

67
Q

Lithium - Pregnancy

A

Potential risk of fetal heart malformations, especially in 1st trimester.
If taken during pregnancy, levels may drop in later stages due to increased GFR.
Lithium passes freely into breast milk.

68
Q

Valproate - Mechanism

A

Unknown, but proposed ideas include affecting GABA levels, blockage of voltage-gated Na+ channels, inhibiting histone deacetylases.

69
Q

Valproate - Pharmacology

A

Half-life 16 hours
Bioavailability close to 100%
90% protein bound (levels may be inaccurate in hypoalbuminaemia, can displace other drugs such as warfarin, phenytoin, carbamazepine)
Metabolised by liver
Loading dose 20-30mg/kg

70
Q

Valproate - Indications

A

Treatment of mania, mixed mood episodes, rapid cycling BPAD
Prophylaxis in BPAD

71
Q

Valproate - Levels

A

Not routinely monitored as poor correlation with therapeutic efficacy.
May be useful in non-adherence, suspected toxicity.
Trough level - 350-700 μmol/L

72
Q

Valproate - Side effects

A

Common = N+V, dry mouth, somnolence, hair loss, peripheral oedema.
Serious = liver failure (monitor LFTs), pancreatitis, increased suicide risk, thrombocytopenia.
Can lead to hyperammonaemic encephalopathy in people with disorders of carnitine metabolism.

73
Q

Valproate - Pregnancy

A

Highly teratogenic
Contraindicated in women of childbearing age

74
Q

Valproate - Interactions

A

Can increase lamotrigine levels by inhibiting gluconuridation

75
Q

Carbamazepine - Mechanism

A

Blocks voltage-gated Na+ channels, reduces glutamate release, decreases adrenaline/NA turnover

76
Q

Carbamazepine - Pharmacology

A

Bioavailability 80%
Variable absorption
75% bound to plasma protein
Induces its own metabolism (CYP3A4)

77
Q

Carbamazepine - Indications

A

Prophylaxis in BPAD, rapid cycling

78
Q

Carbamazepine - Levels

A

Trough level 16-40 μmol/L
Check 4-6 monthly or if dose adjusted

79
Q

Carbamazepine - Side effects

A

Common = drowsiness, headaches, N+V, constipation, dizziness
Serious = severe skin reactions (SJS, toxic epidermal necrolysis), agranulocytosis, aplastic anaemia, porphyria

80
Q

Carbamazepine - Interactions

A
  • Potent CYP3A4 inducer - interacts with OCP, antipsychotics (can decrease levels), methadone, thyroxine
  • Levels may be increased by fluoxetine/paroxetine
  • Contraindicated with clozapine
81
Q

Lamotrigine - Mechanism

A

Blocks voltage-gated Na+ channels, with secondary effect on Ca2+ transport, leading to membrane stabilisation and decreased glutamate release.
Weak 5HT-3 antagonist.

82
Q

Lamotrigine - Pharmacology

A

Half-life 28 hours
55% protein bound

83
Q

Lamotrigine - Indications

A

Prevention of depression in BPAD
Not effective for mania

84
Q

Lamotrigine -rash

A

About 8% get a rash in first 4/12 of tx.
In 0.1%, this is SJS or TEN, so lamotrigine must be stopped at first sign of a rash.
Risk of rash increased with rapid titration, higher doses, co-administration with valproate.

85
Q

Lamotrigine - Interactions

A

Carbamazepine decreases levels by 50%
Valproate increases levels by 50%
COCP induces glucuronidation, increasing excretion x3

86
Q

Gabapentin/Pregabalin

A

Structural analogues of GABA
Bind to voltage-gated Na+ channel
Act on 1-amino acid transporter and increases GABA availability in brain
Anxiolytic, analgesia and anticonvulsant effects

87
Q

Tiagabine

A

Potent inhibitor of GABA uptake into neuros and glial cells, by selective inhibition of GAT1 (GABA transporter)
Used an anticonvulsant, as well as in anxiety and panic disorders

88
Q

Vigabatrin

A

Selective irreversible GABA-transaminase inhibitor
Indicated as anticonvulsant

89
Q

Topiramate

A

Modifies Na+ and Ca2+ dependent channels
Selective inhibitor of kainate-mediated AMPA glutamate receptors
Enhances GABA-mediated Cl- flux into neurons
Potentiates action of GABA-A receptor
Indicated in epilepsy, migraine prophylaxis

90
Q

Benzodiazepines - Mechanism

A

Enhance effect of GABA on GABA-A receptor to decrease excitability of neurons, resulting in sedative, hypnotic, anxiolytic, anticonvulsant and muscle-relaxant properties

91
Q

Benzodiazepines - half-lives

A

Short acting = midazolam (half-life 2hrs), triazolam
Intermediate acting = clonazepam (half-life 19-60hrs), lorazepam (half-life 10-20hrs) and temazepam
Long acting = diazepam (half-life 20-80hrs)

92
Q

Benzodiazepines - Side effects

A

Withdrawal (due to decreased brain GABA function), tolerance and dependence
Drowsiness, dizziness, cognitive impairment (anterograde amnesia)
Paradoxical reactions
Can precipitate coma in hepatic impairment

93
Q

Z-drugs

A

Very similar to benzodiazepines
Used for anxiolytic and hypnotic effects
Mechanism: agonists of GABA-A alpha-1 subunit on omega-1 receptor (also called benzodiazepine-associated receptor), which potentiates GABA
Similar benefits, risks and side effects to benzos

94
Q

Prazosin

A

Alpha-2 presynaptic agonist
Reduces NA in brain to help with hyperarousal and nightmares

95
Q

Clonidine

A

Alpha-2 adrenergic agonist

96
Q

Melatonin

A

Hormone released from pineal gland
Melatonin 1 and 2 receptor agonist
Mixed evidence of efficacy for sleep
Half-life 3-4 hours

97
Q

Promethazine

A

H1 receptor antagonist, anticholinergic
Side effects = headache, antimuscarinic effects, psychomotor impairment, excitation in young/old

98
Q

Methylphenidate

A

Ritalin = immediate release
Concerta = sustained release

Side effects: tachycardia, hypertension, anorexia, dry mouth, GI effects

First line for ADHD

99
Q

N-acetylcysteine

A

Used for paracetamol overdose
Reduces oxidative and neuroinflammatory stress
Can also be used as augmentation agent in mood disorders, especially BPAD

100
Q

Dantrolene

A

Direct or indirect ryanodine receptor antagonist, to decrease intracellular Ca2+ and relax muscles
Used in treatment of rigidity in NMS

101
Q

Flumenazil

A

Selective GABA-A receptor antagonist
Used as antagonist and antidote to benzodiazepines, through competitive inhibition

102
Q

Desfuroxamine

A

Used as antidote in iron overdose

103
Q

BAL

A

Dimercaprol or British anti-Lewisite
Used as antidote in arsenic and lead poisoning

104
Q

Sodium bicarbonate

A

Used to prevent metabolic acidosis in overdose of TCAs

105
Q

Thyroxine

A

Usual maintenance dose 100mcg
Half-life of 7-10 days, but much longer biological effect
Children require larger doses by bodyweight

106
Q

SSRIs - Half-life

A

Fluoxetine has longest half-life = 5-7 days (washout period is about 35 days). Least likely to cause discontinuation sx.
Paroxetine has shortest half-life (21hrs) so has highest risk of discontinuation sx.
Other SSRIs have half-life of 20-72 hours (so washout period about 2 weeks)

107
Q

Ketamine

A

NMDA receptor antagonist
In sub-anaesthetic doses, it non-competitively binds to NMDA receptors as an antagonist

108
Q

Baclofen

A

GABA-B agonist
Used as a muscle relaxant and to reduce alcohol cravings

109
Q

Sildenafil

A

Phosphodiesterase inhibitor
Binds to PDE5 competitively, and inhibit cGMP hydrolysis, leading to an erection.

110
Q

Zero order kinetics

A

When the clearance system is saturated, a constant amount is eliminated. This means the levels in the body will increase with increase in doses, so toxicity can occur.
For example; phenytoin, lithium, depots, alcohol.

111
Q

First order kinetics

A

A constant fraction of the drug is eliminated regardless of dose. The rate of clearance only depends on concentration. Most psychotropics are excreted via first order kinetics.

112
Q

Bioavailability

A

The fraction of the dose that reaches systemic circulation

113
Q

Bioequivalence

A

Measure of the comparability of plasma levels of two different formulations of the same active drug

114
Q

Non-competitive antagonist

A

Binds to receptor at site distinct from active site, and induces a confirmational change in receptor which alters the affinity of the receptor for the endogenous ligand, so that effects cannot be reversed completely by increasing the dose of agonist.

115
Q

Irreversible antagonist

A

Binds to the receptor but cannot be displaced

116
Q

Tigabine

A

A potent inhibitor of GABA uptake into neurons and glial cells, by inhibiting GAT-1, a GABA transporter.
Anticonvulsant.

117
Q

Caffeine

A

Acts as antagonist of adenosine A1 receptors
Half-life 4-6 hours

118
Q

Beta-blockers

A

Overdose leads to hypoglycaemia
Hence treat with glucagon

119
Q

Antidepressant recommended post-MI

A

Sertraline

120
Q

CYP1A2

A

Involved in metabolism of clozapine, olanzapine.
Inducers = smoking
Inhibitors = caffeine, grapefruit, fluvoxamine, ciprofloxacin

121
Q

CYP2D6

A

Involved in metabolism of risperidone, codeine.
Inhibitors = SSRIs (especially paroxetine, fluoxetine)
Significant ethnic differences in rate of metabolism/enzyme levels

122
Q

CYP3A4

A

Involved in metabolism of clozapine, quetiapine, ziprasidone, carbamazepine
Inducers = carbamazepine, phenytoin, barbituates, rifampicin
Inhibitors = erythromycin, ketoconazole, protease inhibitors

123
Q

CYP2C19

A

Inhibitors = fluoxetine, fluvoxamine
Ethnic differences (20% of Japanese/Chinese are deficient)

Psych MCQs (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions